For prostate cancer screening, guidelines have little effect on clinical practice
the ONA take:
According to a new study published online in The Journal of the American Medical Association Internal Medicine, guidelines recommending that clinicians should not routinely screen elderly men for prostate cancer have had a minimal effect on practice. Researchers from Henry Ford Hospital in Detroit, Michigan, sought to find out whether a change in prostate screening guidelines by the U.S. Preventive Services Task Force (USPSTF) had altered practice in the last 3 years since the USPSTF recommended against routine prostate specific antigen (PSA) testing in any age group.
By using the 2012 Behavioral Risk Factor Surveillance System, the researchers examined which factors influence whether a patient is screened for prostate cancer, including access to health care, age, education, ethnicity/race, geographic location, income, insurance status, and marital status. They found that access to regular health care was strongly associated with increased rates of PSA screening.
In addition, they found an association between screening and an income greater than $75,000, higher education, health insurance, and an age between 70 and 74. Surprisingly, Hawaii has double the rate of PSA screening compared with New Hampshire.
The researchers suggest that the USPSTF guidelines have little effect on clinical practice.
Guidelines recommending not routinely screening have had a minimal effect on practice.
The effect of guidelines recommending that elderly men should not be routinely screened for prostate cancer "has been minimal at best," according to a new study led by researchers at Henry Ford Hospital.
The study, published as a research letter online in JAMA Internal Medicine, focused on the use of PSA - prostate-specific antigen - to test for prostate cancer. "We found that the effect of the guidelines recommending against the routine screening of elderly men in particular has been minimal at best," says Jesse Sammon, D.O., a researcher at Henry Ford's Vattikuti Urology Institute and lead author of the study.
The researchers found an estimated 17 million men age 50 or older without a history of prostate cancer or prostate problems who reported undergoing PSA screening. Though credited with a significant improvement in 5-year cancer survival rates during the first decade after the FDA approved PSA testing of men without symptoms, its use for routine screening is controversial.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|